BRPI0811617A2 - derivados de primidina e composições como inibidores de c-kit e pdgfr quinase. - Google Patents

derivados de primidina e composições como inibidores de c-kit e pdgfr quinase.

Info

Publication number
BRPI0811617A2
BRPI0811617A2 BRPI0811617A BRPI0811617A BRPI0811617A2 BR PI0811617 A2 BRPI0811617 A2 BR PI0811617A2 BR PI0811617 A BRPI0811617 A BR PI0811617A BR PI0811617 A BRPI0811617 A BR PI0811617A BR PI0811617 A2 BRPI0811617 A2 BR PI0811617A2
Authority
BR
Brazil
Prior art keywords
kit
derivatives
compositions
primidine
kinase inhibitors
Prior art date
Application number
BRPI0811617A
Other languages
English (en)
Inventor
Molteni Valentina
Lu Xiaodong
Li Xiaolin
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of BRPI0811617A2 publication Critical patent/BRPI0811617A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
BRPI0811617A 2007-05-04 2008-05-01 derivados de primidina e composições como inibidores de c-kit e pdgfr quinase. BRPI0811617A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91603507P 2007-05-04 2007-05-04
PCT/US2008/062304 WO2008137605A1 (en) 2007-05-04 2008-05-01 Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0811617A2 true BRPI0811617A2 (pt) 2017-06-06

Family

ID=39616606

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811617A BRPI0811617A2 (pt) 2007-05-04 2008-05-01 derivados de primidina e composições como inibidores de c-kit e pdgfr quinase.

Country Status (13)

Country Link
US (1) US8268850B2 (pt)
EP (1) EP2148874B1 (pt)
JP (1) JP5160636B2 (pt)
KR (1) KR101122481B1 (pt)
CN (1) CN101687853A (pt)
AT (1) ATE544761T1 (pt)
AU (1) AU2008247668B2 (pt)
BR (1) BRPI0811617A2 (pt)
CA (1) CA2686378C (pt)
EA (1) EA017269B1 (pt)
ES (1) ES2381318T3 (pt)
MX (1) MX2009011950A (pt)
WO (1) WO2008137605A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017392B1 (ru) 2007-08-22 2012-12-28 Айрм Ллк Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ
MX2010002004A (es) 2007-08-22 2010-03-11 Irm Llc Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones con inhibidores de cinasa.
CN102083828B (zh) 2008-02-22 2013-11-13 Irm责任有限公司 作为c-kit和pdgfr激酶抑制剂的杂环化合物和组合物
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
WO2011075560A1 (en) 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
BR112012014703B1 (pt) 2009-12-17 2021-08-03 Merck Sharp & Dohme Corp. Composto aminopirimidina inibidor de syk, e, composição farmacêutica
JP6147727B2 (ja) * 2011-04-01 2017-06-14 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション チロシン受容体キナーゼbtk阻害剤としての置換n−(3−(ピリミジン−4−イル)フェニル)アクリルアミド類似体
PL2693881T3 (pl) 2011-04-01 2020-03-31 University Of Utah Research Foundation Podstawione analogi N-fenylopirymidyno-2-aminy jako inhibitory kinazy AXL
EP2707357B1 (en) 2011-05-10 2017-01-18 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
WO2012154518A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
MX2013013090A (es) 2011-05-10 2013-12-16 Merck Sharp & Dohme Aminopirimidinas como inhibidores de tirosina cinaza del bazo.
EP3680238A1 (en) 2012-10-04 2020-07-15 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
JP6313772B2 (ja) 2012-10-04 2018-04-18 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション チロシン受容体キナーゼbtk阻害剤である置換n−(3−(ピリミジン−4−イル)フェニル)アクリルアミド類似体
EP3007689B1 (en) 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
KR102334260B1 (ko) 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Jak2 및 alk2 억제제 및 이들의 사용 방법
CN104458674A (zh) * 2013-09-12 2015-03-25 中国药科大学 一种筛选血管内皮生长因子1激酶抑制剂高通量筛选方法
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
WO2018081567A1 (en) 2016-10-27 2018-05-03 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
AU2019223911A1 (en) * 2018-02-21 2020-07-23 Melior Pharmaceuticals I, Inc. Treatment of liver diseases
WO2019195753A1 (en) 2018-04-05 2019-10-10 Tolero Pharmaceuticals, Inc. Axl kinase inhibitors and use of the same
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
TWI759829B (zh) * 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
CN112745300A (zh) * 2021-01-21 2021-05-04 杭州浙中医药科技有限公司 一种制备n-(5-羧基-2-甲基苯基)-4-(3-吡啶)-2-嘧啶胺的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0164204A1 (en) 1984-05-12 1985-12-11 FISONS plc Novel pharmaceutically useful pyrimidines
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
CA2446939C (en) * 2001-05-16 2005-08-02 Matthias Stein-Gerlach Pyridylpyrimidine derivatives as effective compounds against prion diseases
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
CA2591321C (en) * 2004-09-09 2013-09-24 Natco Pharma Limited Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
CN101039919A (zh) * 2004-10-13 2007-09-19 惠氏公司 经n-苯磺酰基取代的苯胺基嘧啶类似物
MX2007011500A (es) 2005-03-16 2007-11-21 Targegen Inc Compuestos pirimidina y metodos de uso.
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
AU2006297089B2 (en) 2005-09-27 2012-05-03 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
WO2008137794A1 (en) 2007-05-04 2008-11-13 Irm Llc Compounds and compositions as c-kit and pdgfr kinase inhibitors
MX2009011952A (es) * 2007-05-04 2009-12-11 Irm Llc Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.

Also Published As

Publication number Publication date
CN101687853A (zh) 2010-03-31
EP2148874A1 (en) 2010-02-03
MX2009011950A (es) 2009-12-11
JP2010526148A (ja) 2010-07-29
AU2008247668B2 (en) 2013-01-10
KR101122481B1 (ko) 2012-02-29
WO2008137605A1 (en) 2008-11-13
JP5160636B2 (ja) 2013-03-13
EA200901483A1 (ru) 2010-04-30
US8268850B2 (en) 2012-09-18
ES2381318T3 (es) 2012-05-25
ATE544761T1 (de) 2012-02-15
CA2686378A1 (en) 2008-11-13
EA017269B1 (ru) 2012-11-30
AU2008247668A1 (en) 2008-11-13
CA2686378C (en) 2012-07-24
US20100190811A1 (en) 2010-07-29
EP2148874B1 (en) 2012-02-08
KR20090130342A (ko) 2009-12-22

Similar Documents

Publication Publication Date Title
BRPI0811617A2 (pt) derivados de primidina e composições como inibidores de c-kit e pdgfr quinase.
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MY167245A (en) Compounds and compositions as c-kit kinase inhibitors
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
TN2014000068A1 (en) Compounds and compositions as c-kit kinase inhibitors
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
ECSP099378A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
TW200637547A (en) Compounds and compositions as protein kinase inhibitors
CR11430A (es) 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpirimidin-2-aminas como inhibidores de cinasas janus
EA201071089A1 (ru) Производные хиназолина как модуляторы raf-киназы и способы их применения
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
EA201490537A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ C-Kit
WO2009097287A9 (en) Compounds and compositions as kinase inhibitors
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
EA201490539A1 (ru) Соединения и композиции в качестве ингибиторов c-kit киназы
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
BR112013009260A2 (pt) compostos de carboxamida de piridazina substituídos como compostos inibidores de quinase
BR112013008523A2 (pt) compostos de piridazina carboxamida substituídos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]